This technology includes methods for the biofabrication of full thickness skin tissues in 12, 24, 48 and 96-well plates, using commercially available hardware to enable the implementation of large-scale toxicity and efficacy testing of chemical and biologics. The invention includes several protocols, including but not limited to: 1) fully 3D bioprinted skin tissue with dermis composed of human fibroblast and a collagen/fibrin/gelatin-based hydrogel; a coating of laminin, and a stratified epidermis composed of human neonatal keratinocytes, all on top of a commercially available transwell insert membrane. 2) A 3D bioprinted skin tissue protocol with a dermis composed on human fibroblasts and a collagen/fibrin/gelatin-based hydrogel which is bioprinted on the bottom side of the transwell well insert membrane; and keratinocytes that are added on top of the insert membrane to develop a stratified epidermis.